<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>药事纵横 | wechat-feeds</title><link>http://MzI5ODI5NDE2OA.favicon.privacyhide.com/favicon.ico</link><description>药事纵横是一个由多位制药精英联合创办的媒体平台，旨在分享与传递药品研发、生产和注册中所涉及的技术、经验和情报，欢迎关注和投稿！投稿请发442015666@qq.com</description><managingEditor> (hellodword)</managingEditor><pubDate>Fri, 05 Feb 2021 07:30:26 +0800</pubDate><image><url>http://MzI5ODI5NDE2OA.favicon.privacyhide.com/favicon.ico</url><title>药事纵横 | wechat-feeds</title><link>http://MzI5ODI5NDE2OA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>CDE对制剂工艺中过量灌装与过量投料的审评尺度</title><link>https://mp.weixin.qq.com/s/64WJkaENQ3aWZMYR8lhp3w</link><description></description><content:encoded><![CDATA[CDE对制剂工艺中过量灌装与过量投料的审评尺度]]></content:encoded><pubDate>Thu, 04 Feb 2021 20:49:13 +0800</pubDate></item><item><title>工业百强榜药企-天地恒一药物研究院高级岗位招聘！不缺平台，不缺机会，我们相约幸福之城！</title><link>https://mp.weixin.qq.com/s/OjQBE8bGttzrLiXpEU1E4A</link><description></description><content:encoded><![CDATA[工业百强榜药企-天地恒一药物研究院高级岗位招聘！不缺平台，不缺机会，我们相约幸福之城！]]></content:encoded><pubDate>Thu, 04 Feb 2021 20:49:13 +0800</pubDate></item><item><title>9张图，穿透第四批集采各项细节：规模缩水、产品与市场排名变化,谁是最大的赢家？......</title><link>https://mp.weixin.qq.com/s/VDNoLY2DVhgAGaYjKJPzbg</link><description></description><content:encoded><![CDATA[9张图，穿透第四批集采各项细节：规模缩水、产品与市场排名变化,谁是最大的赢家？......]]></content:encoded><pubDate>Thu, 04 Feb 2021 20:49:13 +0800</pubDate></item><item><title>FDA批准Tepotinib用于MET外显子14跳跃突变的非小细胞肺癌治疗</title><link>https://mp.weixin.qq.com/s/7XcptWB5gjRfOxi8iVTGCg</link><description></description><content:encoded><![CDATA[FDA批准Tepotinib用于MET外显子14跳跃突变的非小细胞肺癌治疗]]></content:encoded><pubDate>Thu, 04 Feb 2021 20:49:13 +0800</pubDate></item><item><title>官方公布第四轮集采拟中标结果，谁家欢喜谁家愁？</title><link>https://mp.weixin.qq.com/s/gmkgQZJO_uuF_IInzrcWyg</link><description></description><content:encoded><![CDATA[官方公布第四轮集采拟中标结果，谁家欢喜谁家愁？]]></content:encoded><pubDate>Thu, 04 Feb 2021 07:50:32 +0800</pubDate></item><item><title>集采后，产品市场要变天</title><link>https://mp.weixin.qq.com/s/MdlgiuOLjI6_Pba0UK6B3g</link><description></description><content:encoded><![CDATA[集采后，产品市场要变天]]></content:encoded><pubDate>Thu, 04 Feb 2021 07:50:32 +0800</pubDate></item><item><title>一文秒懂“清洁分析方法验证中擦拭回收试验”</title><link>https://mp.weixin.qq.com/s/IxPT8SJcdZgwJHOsqRMblQ</link><description></description><content:encoded><![CDATA[一文秒懂“清洁分析方法验证中擦拭回收试验”]]></content:encoded><pubDate>Thu, 04 Feb 2021 07:50:32 +0800</pubDate></item><item><title>安瓿瓶密封性研究实践 兼谈包装系统密封性研究常见误区</title><link>https://mp.weixin.qq.com/s/43fPHdyGAqvJroiNXgpEFA</link><description></description><content:encoded><![CDATA[安瓿瓶密封性研究实践 兼谈包装系统密封性研究常见误区]]></content:encoded><pubDate>Tue, 02 Feb 2021 20:22:17 +0800</pubDate></item><item><title>老牌CRO的强势布局升级——一位17年老员工眼中的上海睿智</title><link>https://mp.weixin.qq.com/s/xRjqP97ZPszddaXbewkmUA</link><description></description><content:encoded><![CDATA[老牌CRO的强势布局升级——一位17年老员工眼中的上海睿智]]></content:encoded><pubDate>Tue, 02 Feb 2021 20:22:17 +0800</pubDate></item><item><title>带量采购：报价、开标、开标之后的应对方式</title><link>https://mp.weixin.qq.com/s/KnRJDJT4bxna1UC7Oom3dA</link><description></description><content:encoded><![CDATA[带量采购：报价、开标、开标之后的应对方式]]></content:encoded><pubDate>Tue, 02 Feb 2021 20:22:17 +0800</pubDate></item><item><title>原料药、化药制剂和中成药定量测定时的回收率考察方法探讨</title><link>https://mp.weixin.qq.com/s/0mq9OSUxaDb8qFZ3dO-mWg</link><description></description><content:encoded><![CDATA[原料药、化药制剂和中成药定量测定时的回收率考察方法探讨]]></content:encoded><pubDate>Tue, 02 Feb 2021 20:22:17 +0800</pubDate></item><item><title>色谱学中Van Deemter方程的浅析</title><link>https://mp.weixin.qq.com/s/rfEmUcvOCWwspSUh2mLLRQ</link><description></description><content:encoded><![CDATA[色谱学中Van Deemter方程的浅析]]></content:encoded><pubDate>Tue, 02 Feb 2021 10:08:03 +0800</pubDate></item><item><title>读阿斯利康百年发家史：成功和失败都只是过程，而非结果</title><link>https://mp.weixin.qq.com/s/S7cHosVeGU0YO6r_2wR9-g</link><description></description><content:encoded><![CDATA[读阿斯利康百年发家史：成功和失败都只是过程，而非结果]]></content:encoded><pubDate>Tue, 02 Feb 2021 10:08:03 +0800</pubDate></item><item><title>基于原料药性质的口服固体制剂生产工艺路线选择</title><link>https://mp.weixin.qq.com/s/J0NzMsSVuZQcDWdShU3k2g</link><description></description><content:encoded><![CDATA[基于原料药性质的口服固体制剂生产工艺路线选择]]></content:encoded><pubDate>Tue, 02 Feb 2021 10:08:03 +0800</pubDate></item><item><title>药事纵横广告投放须知</title><link>https://mp.weixin.qq.com/s/IjXM-1OT84-vm9ny2bwMdA</link><description></description><content:encoded><![CDATA[药事纵横广告投放须知]]></content:encoded><pubDate>Tue, 02 Feb 2021 10:08:03 +0800</pubDate></item><item><title>从独眼羊到抗癌新药</title><link>https://mp.weixin.qq.com/s/uISlu0j611xQj0_ta_TyXQ</link><description></description><content:encoded><![CDATA[从独眼羊到抗癌新药]]></content:encoded><pubDate>Mon, 01 Feb 2021 09:02:08 +0800</pubDate></item><item><title>PROTAC技术详梳理-2-分子与结构机理篇</title><link>https://mp.weixin.qq.com/s/IP1IFs0l_GHz-H4tl9Uk_g</link><description></description><content:encoded><![CDATA[PROTAC技术详梳理-2-分子与结构机理篇]]></content:encoded><pubDate>Mon, 01 Feb 2021 09:02:08 +0800</pubDate></item><item><title>高效液相检验时重复样与进针次数讨论</title><link>https://mp.weixin.qq.com/s/ICfYLanaQg2PymKXd9rxxg</link><description></description><content:encoded><![CDATA[高效液相检验时重复样与进针次数讨论]]></content:encoded><pubDate>Mon, 01 Feb 2021 09:02:08 +0800</pubDate></item><item><title>药事纵横征稿启事</title><link>https://mp.weixin.qq.com/s/ZIuXFkneiZ1PaZlYavvqYg</link><description></description><content:encoded><![CDATA[药事纵横征稿启事]]></content:encoded><pubDate>Mon, 01 Feb 2021 09:02:08 +0800</pubDate></item><item><title>FDA批准的老药新用案例总结：创新药太贵，就试试老药二次创新</title><link>https://mp.weixin.qq.com/s/b7p8aArl9ErOK-Z1S8YiDQ</link><description></description><content:encoded><![CDATA[FDA批准的老药新用案例总结：创新药太贵，就试试老药二次创新]]></content:encoded><pubDate>Sat, 30 Jan 2021 22:09:59 +0800</pubDate></item></channel></rss>